LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

导出原文传递

翻译打印收藏纠错

作者： Rorick-Kehn,L.M. ^[1] ; Witkin,J.M. ; Statnick,M.A. ; Eberle,E.L. ; McKinzie,J.H. ; Kahl,S.D. ; Forster,B.M. ; Wong,C.J. ; Li,X. ; Crile,R.S. ; Shaw,D.B. ; Sahr,A.E. ; Adams,B.L. ; Quimby,S.J. ; Diaz,N. ; Jimenez,A. ; Pedregal,C. ; Mitch,C.H. ; Knopp,K.L. ; Anderson,W.H. ; Cramer,J.W. ; McKinzie,D.L.

作者单位： Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, United States ^[1]

关键词 Addiction Alcohol dependence Antidepressant Dynorphin Kappa opioid antagonist Opioid receptors

发布时间 2014-03-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Neuropharmacology

2014年77卷

131-144页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

Neuropharmacology

相似文献

Neuropharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

Neuropharmacology

相似文献

Neuropharmacology

相关期刊

检索历史清除